Details for Patent: 8,534,281

Which drugs does patent 8,534,281 protect, and when does it expire?

Patent 8,534,281 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 8,534,281

Title:	Manifold for use in medicament dispenser
Abstract:	A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from said chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit, wherein the chimney exit and the chamber inlet lie side-by-side each other such that when the open blister pocket of the blister pack is positioned adjacent thereto the airflow is directed from the chimney exit to the chamber inlet via the open blister pocket to entrain the medicament powder and enable transport thereof in the airflow from the chamber inlet to the chamber exit, and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder.
Inventor(s):	Davies; Michael Birsha (Ware, GB), Hailey; Mark Andrew (Ware, GB), Palmer; Mark Gregory (Ware, GB), Walker; Richard Ian (Ware, GB)
Assignee:	Glaxo Group Limited (Greenforo, Middlesex, GB)
Application Number:	12/096,820
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,534,281
Patent Claim Types: see list of patent claims	Delivery; Device; Use;

Recent additions to Drugs Protected by US Patent 8,534,281

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use

Drugs Protected by US Patent 8,534,281

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,534,281

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0525237.4	Dec 12, 2005
United Kingdom	0623405.8	Nov 23, 2006

PCT Information
PCT Filed	December 11, 2006	PCT Application Number:	PCT/GB2006/004612
PCT Publication Date:	June 21, 2007	PCT Publication Number:	WO2007/068896

International Family Members for US Patent 8,534,281

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	058289
Australia	2006324478
Brazil	PI0619732
Canada	2631889